Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
L
L

LaboratoryCorporation

Balita

Reuters - 57 minuto ang nakaraan

Cinven To Sell Minority Stake In SYNLAB To Labcorp

BRIEF-Cinven To Sell Minority Stake In SYNLAB To Labcorp Sept 17 (Reuters) - Cinven: CINVEN: TO SELL MINORITY STAKE IN SYNLAB TO LABCORP CINVEN: PURCHASE PRICE FOR INDIRECT MINORITY STAKE OF 15% WAS ABOUT EUR 140 MILLION Further company coverage: LH.N
L
Reuters - 1 araw ang nakaraan

Labcorp Completes Acquisition Of Select Assets Of Bioreference Health's Diagnostics Business From Opko Health

BRIEF-Labcorp Completes Acquisition Of Select Assets Of Bioreference Health's Diagnostics Business From Opko Health Sept 16 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP COMPLETES ACQUISITION OF SELECT ASSETS OF BIOREFERENCE HEALTH'S DIAGNOSTICS BUSINESS FROM OPKO HEALTH Source text for Eikon: ID:nPnbrzkBja Further company coverage: LH.N
O
L
Reuters - 4 araw ang nakaraan

U.S. Constellation Energy, Eli Lilly, Talen Energy

U.S. RESEARCH ROUNDUP-Constellation Energy, Eli Lilly, Talen Energy Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday. HIGHLIGHTS * Constellation Energy Corp CEG.O : Jefferies initiates with hold rating; target $183 * Eli Lilly LLY.N : JP Morgan raises target price to $1,100 from $1,050 * Moderna MRNA.O : JP Morgan cuts to underweight from neutral * Vo
A
C
C
F
F
H
H
H
I
K
W
F
D
T
Z
A
A
D
E
H
L
Reuters - 5 araw ang nakaraan

Origin of human bird flu case in Missouri still unknown, U.S. CDC says

UPDATE 1-Origin of human bird flu case in Missouri still unknown, U.S. CDC says Adds context in paragraphs 7-12, bylines By Leah Douglas and Julie Steenhuysen WASHINGTON, Sept 12 (Reuters) - Epidemiologists have not yet identified exactly how a person in Missouri contracted bird flu last week, said the U.S. Centers for Disease Control and Prevention on Thursday.
L
Reuters - 5 araw ang nakaraan

Origin of human bird flu case in Missouri still unknown, U.S. CDC says

RPT-Origin of human bird flu case in Missouri still unknown, U.S. CDC says Repeats URGENT to attach to snaps WASHINGTON, Sept 12 (Reuters) - Epidemiologists have not yet identified exactly how a person in Missouri contracted bird flu last week, said the U.S. Centers for Disease Control and Prevention on Thursday. The human case was the 14th diagnosed in the U.S.
L
Reuters - 2 linggo ang nakaraan

U.S. Coca-Cola, KB Home, Newmark Group

U.S. RESEARCH ROUNDUP-Coca-Cola, KB Home, Newmark Group Sept 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, KB Home and Newmark Group on Thursday. HIGHLIGHTS * Capital Clean Energy Carriers CCEC.O : Evercore ISI initiates coverage with outperform rating * Coca-Cola Co KO.N : CFRA cuts to hold from buy * KB Home KBH.N : RBC cuts to underperform from sector perform * Newmark Group Inc NMRK.O : KBW raises
B
U
C
D
C
C
L
Reuters - 3 linggo ang nakaraan

WHO invites makers of mpox tests for emergency review in push for rapid access

UPDATE 2-WHO invites makers of mpox tests for emergency review in push for rapid access Adds details and background throughout Aug 29 (Reuters) - The World Health Organization on Thursday s ought to speed up the access to diagnostic tests for mpox by asking manufacturers to submit their products for an emergency review. The agency has been in discussions with manufacturers about the need for effective diagnostics, particularly in low-income g roups .
L
Reuters - 3 linggo ang nakaraan

Diagnostics firm Labcorp weighs ramping up mpox testing capacity

UPDATE 2-Diagnostics firm Labcorp weighs ramping up mpox testing capacity Adds details on other tests from paragraph 6 By Sneha S K Aug 26 (Reuters) - Diagnostics firm Labcorp LH.N said it is working with U.S. health regulators to determine if it needed to ramp up its mpox testing capacity, as countries outside Africa detect a new type of the virus for the first time.
A
L
Reuters - 3 linggo ang nakaraan

Labcorp Says It Has Capacity To Process About 25,000 Mpox Tests Per Month

BRIEF-Labcorp Says It Has Capacity To Process About 25,000 Mpox Tests Per Month Aug 26 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP SAYS IT IS WORKING CLOSELY WITH US CDC AND PUBLIC HEALTH AGENCIES TO MONITOR MPOX OUTBREAK AND WEIGH NEED FOR INCREASED SUPPLIES OR TESTING LABCORP SAYS CURRENTLY PROCESSING ABOUT 500 MPOX TESTS A MONTH, BUT HAVE CA
L
Reuters - 4 linggo ang nakaraan

Labcorp Says, Co, Units, Entered Into A Three-Year $300 Mln Accounts Receivable Securitization Facility

BRIEF-Labcorp Says, Co, Units, Entered Into A Three-Year $300 Mln Accounts Receivable Securitization Facility Aug 23 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP - CO, UNITS, ENTERED INTO A THREE-YEAR $300 MILLION ACCOUNTS RECEIVABLE SECURITIZATION FACILITY LABCORP - SECURITIZATION FACILITY CONTAINS ACCORDION TO INCREASE FACILITY LIMIT UP TO $70
L
Reuters - 4 linggo ang nakaraan

PreciseDx Secures $20.7 Million Series B to Advance Powered Cancer Risk Assessments

BRIEF-PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments Aug 21 (Reuters) - Quest Diagnostics Inc DGX.N : PRECISEDX: RAISED $20.7 MILLION IN SERIES B FUNDING, BRINGING TOTAL FUNDING TO DATE TO $31.5 MILLION PRECISEDX: ADDITIONAL PARTICIPANTS IN ROUND INCLUDE LABCORP, QUEST DIAGNOSTICS, GENHENN CAPITAL VENTURE Sou
L
Reuters - 4 linggo ang nakaraan

U.S. Agree Realty, Global Payments, Snowflake

U.S. RESEARCH ROUNDUP- Agree Realty, Global Payments, Snowflake Aug 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agree Realty, Global Payments and Snowflake on Wednesday. HIGHLIGHTS * Agree Realty Corp ADC.N : Raymond James raises target price to $81 from $70 * Coinbase Global Inc COIN.O : Jefferies cuts target price to $220 from $245 * Global Payments Inc GPN.N : Jefferies raises target price to $130 from $120
A
B
C
C
P
V
E
G
M
K
L
Reuters - 1 buwan ang nakaraan

Labcorp Finalizes Acquisition Of Select Assets Of Invitae

BRIEF-Labcorp Finalizes Acquisition Of Select Assets Of Invitae Aug 5 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP FINALIZES ACQUISITION OF SELECT ASSETS OF INVITAE Source text for Eikon: ID:nPn1nRrF1a Further company coverage: LH.N
L
Reuters - 2 buwan ang nakaraan

Labcorp Receives FDA De Novo Marketing Authorization For Pgdx Elio™ Plasma Focus Dx

BRIEF-Labcorp Receives FDA De Novo Marketing Authorization For Pgdx Elio™ Plasma Focus Dx Aug 2 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP RECEIVES FDA DE NOVO MARKETING AUTHORIZATION FOR PGDX ELIO™ PLASMA FOCUS DX Source text for Eikon: ID:nPnYSv1Ra Further company coverage: LH.N
L
Reuters - 2 buwan ang nakaraan

U.S. Apple, Centerpoint Energy, Cummins

U.S. RESEARCH ROUNDUP-Apple, Centerpoint Energy, Cummins Aug 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Apple, Centerpoint Energy and Cummins, on Friday. HIGHLIGHTS * Apple Inc AAPL.O : Wedbush raises target price to $285 from $275 * Centerpoint Energy CNP.N : JP Morgan cuts to neutral from overweight * Cummins CMI.N : Jefferies raises target price to $365 from $345 * Motorola MSI.N : JP Morgan raises target pr
A
A
B
B
I
K
M
A
B
C
A
A
A
A
C
C
L
M
Reuters - 2 buwan ang nakaraan

U.S. STOCKS Spirit Airlines, Labcorp, Air Products and Chemicals

BUZZ-U.S. STOCKS ON THE MOVE-Spirit Airlines, Labcorp, Air Products and Chemicals Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes fell over 1% on Thursday, bogged down by megacap tech and chip stocks, while small-caps bore the brunt of selling pressure as weak manufacturing data renewed concerns around a slowdown in the U.S.
B
I
J
Q
W
C
U
U
A
B
F
L
T
Reuters - 2 buwan ang nakaraan

Labcorp rises after beating Q2 profit and revenue estimates

BUZZ-Labcorp rises after beating Q2 profit and revenue estimates ** Shares of Labcorp LH.N rise as much as 7.7% to an over six-month high of $232 ** Lab operator's Q2 adj. EPS of $3.94 beats Wall Street estimates of $3.78 - LSEG ** Q2 revenue of $3.22 bln tops estimates of $3.19 bln ** However, co lowers its annual adj. EPS forecast to $14.30 to $1
L
Reuters - 2 buwan ang nakaraan

Labcorp Holdings Inc reports results for the quarter ended in June - Earnings Summary

Labcorp Holdings Inc reports results for the quarter ended in June - Earnings Summary Labcorp Holdings Inc LH.N reported quarterly adjusted earnings of $3.94​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $3.80. The mean expectation of sixteen analysts for the quarter was for earnings of $3.78 per share.
L
Reuters - 2 buwan ang nakaraan

Labcorp beats Q2 profit and revenue estimates on demand for health tests

Labcorp beats Q2 profit and revenue estimates on demand for health tests Aug 1 (Reuters) - Labcorp LH.N beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic tests, and raised its sales growth forecast for the year. The lab operator now sees annual sales growth between 6.4% and 7.5%, up from its previous range of 4.8% to 6.4%, boosted by demand for diagnostic health tests in the United States that has grown in recent quarters due to a
L
Reuters - 2 buwan ang nakaraan

Labcorp Holdings Inc <LH.N> expected to post earnings of $3.78 a share - Earnings Preview

Labcorp Holdings Inc expected to post earnings of $3.78 a share - Earnings Preview Labcorp Holdings Inc LH.N , LH is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Burlington North Carolina-based company is expected to report a 5.0% increase in revenue to $3.185 billion from $3.03 billion a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
L

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.